Mylan is one of the world's leading generic and specialty pharmaceutical companies, serving customers in more than 140 countries and territories. The company was founded in 1961 and is headquartered in the U.S.

Mylan has one of the industry's broadest and highest quality portfolios, whose more than 900 individual products cover a vast array of therapeutic categories, dosage forms and delivery systems. Mylan also operates Matrix, one of the world's largest manufacturers of active pharmaceutical ingredients (API), and runs Dey Pharma, L.P., a business focused on respiratory and allergy therapies.

The company's reputation for integrity has helped it achieve and sustain strong positions in many established generics markets and is helping it build share in several emerging pharmaceutical markets. Its commercial activities are supported by a fully integrated global technical operations platform. Mylan uses the platform to manage the production process from end to end, so as to offer drugs people can trust.

Mylan also has a long and unwavering dedication to supporting philanthropic causes, from the orphan drugs it manufactures for very small populations, to its ARV franchise, which helps a great many.

Delivering good health around the corner and across the world is the powerful aspiration motivating the company's approximately 15,000 employees, all of whom also are guided by Mylan's culture and values.

The company's goal is to become the world's most efficient generics and specialty pharmaceutical company, allowing it to provide affordable medications to more people in more places than ever before. Because at Mylan, anything less isn't good enough.